News & Updates
Showing Multidisciplinary articles
Showing
ICON8B OS data support a new SoC for epithelial ovarian cancer
In the final overall survival (OS) analysis of the phase III ICON8B trial, first-line treatment with bevacizumab in combination with a chemotherapeutic regimen comprising carboplatin Q3W and dose-dense paclitaxel QW improved survival in women with high-risk stage III-IV epithelial ovarian cancer.
ICON8B OS data support a new SoC for epithelial ovarian cancer
29 Oct 2025
What’s hot at APS & MCV 2025?
MIMS Doctor brings you extensive coverage of the Asia Pneumonia Summit & MasterClass in Vaccinology 2025, held recently in Taipei, Taiwan. Check out the latest updates on RSV, pneumococcal disease, new vaccines, plus thought-provoking insights from respiratory experts. [READ THE FULL REPORT]
What’s hot at APS & MCV 2025?
29 Oct 2025
Obesity linked to COVID-19 severity in children during pre-Omicron wave
A recent study has found that individuals with obesity had more severe COVID-19 during the ancestral and pre-Omicron waves, but not during the Omicron wave.
Obesity linked to COVID-19 severity in children during pre-Omicron wave
28 Oct 2025
Nivolumab bests ipilimumab in head-to-head melanoma trial
The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
Young-onset diabetes: Novel insights on management
At EmW 2025, Professor Andrea Luk from the Department of Medicine & Therapeutics, the Chinese University of Hong Kong, shared insights and recommendations on management of young-onset diabetes (YoD).
